

Ataru Igarashi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/625803/publications.pdf>

Version: 2024-02-01

121
papers

2,083
citations

411340

20
h-index

325983

40
g-index

124
all docs

124
docs citations

124
times ranked

2791
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-effectiveness analyses of biologic and targeted synthetic disease-modifying anti-rheumatic diseases in patients with rheumatoid arthritis: Three approaches with a cohort simulation and real-world data. <i>Modern Rheumatology</i> , 2023, 33, 302-311.	0.9	4
2	Health-Related Quality of Life during COVID-19 Pandemic: Assessing Impacts of Job Loss and Financial Support Programs in Japan. <i>Applied Research in Quality of Life</i> , 2022, 17, 541-557.	1.4	37
3	Cost-effectiveness analysis of endoscopic resection for colorectal laterally spreading tumors: Endoscopic submucosal dissection versus piecemeal endoscopic mucosal resection. <i>Digestive Endoscopy</i> , 2022, 34, 553-568.	1.3	10
4	Cost-Effectiveness Analysis of Omalizumab for Severe Allergic Asthma in Japan Using Real-World Evidence. <i>Value in Health Regional Issues</i> , 2022, 27, 41-48.	0.5	1
5	The impact of omalizumab on paid and unpaid work productivity among severe Japanese cedar pollinosis (JCP) patients. <i>Journal of Medical Economics</i> , 2022, 25, 220-229.	1.0	1
6	Impact of reimbursement restriction on drug market sales under the National Health Insurance in Japan. <i>Journal of Medical Economics</i> , 2022, 25, 206-211.	1.0	2
7	Public preferences and willingness to accept a hypothetical vaccine to prevent a pandemic in Japan: a conjoint analysis. <i>Expert Review of Vaccines</i> , 2022, 21, 241-248.	2.0	7
8	Response to Feemster KA et al. letter to the editor on Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan. <i>Expert Review of Vaccines</i> , 2022, , .	2.0	0
9	Do health preferences differ among Asian populations? A comparison of EQ-5D-5L discrete choice experiments data from 11 Asian studies. <i>Quality of Life Research</i> , 2022, 31, 2175-2187.	1.5	5
10	Cost-saving prediction model of transfer to palliative care for terminal cancer patients in a Japanese general hospital. <i>Journal of Market Access & Health Policy</i> , 2022, 10, 2057651.	0.8	0
11	Systematic Literature Review of Clinical and Economic Evidence for Spinal Muscular Atrophy. <i>Advances in Therapy</i> , 2022, 39, 1915-1958.	1.3	4
12	Burden of illness associated with pneumococcal infections in Japan - a targeted literature review. <i>Journal of Market Access & Health Policy</i> , 2022, 10, 2010956.	0.8	3
13	Drug Utilization and Medical Cost Study Focusing on Moisturizers in Cancer Patients Treated with Molecular Targeted Therapy: A Retrospective Observational Study Using Data from a Japanese Claims Database. <i>Dermatology and Therapy</i> , 2022, 12, 1041-1054.	1.4	0
14	Improvement in prescriptions while maintaining overall health outcomes: a prospective observational study conducted in Japanese facilities for older people. <i>BMC Geriatrics</i> , 2022, 22, 323.	1.1	0
15	Validity of the COmprehensive Score for financial Toxicity (COST) in patients with gynecologic cancer. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 1189-1195.	1.2	3
16	The CeCORD-J study on collagenase injection versus aponeurectomy for Dupuytren's contracture compared by hand function and cost effectiveness. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
17	4 1/4 Žã 1/2 ãã, ãã, ãã f 1/4 Ÿã 1/2 ãã, ãã, ãã f 1/4 Ÿã CEã, “é«~é;è—→ã%ã®è2»ç””ã-3/4ãŠ1æžœããã. <i>Japanese Journal of Clinical Pharmacology and Ther</i>		
18	Cost-Effectiveness Analysis of Initiating Type 2 Diabetes Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor Versus Conventional Therapy in Japan. <i>Diabetes Therapy</i> , 2022, 13, 1367-1381.	1.2	9

#	ARTICLE	IF	CITATIONS
19	Efficacy and safety of tacrolimus in patients with rheumatoid arthritis – A systematic review and meta-analysis. <i>Modern Rheumatology</i> , 2021, 31, 61-69.	0.9	8
20	Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment. <i>Advances in Therapy</i> , 2021, 38, 721-738.	1.3	25
21	How Do Respondents Interpret and View the EQ-VAS? A Qualitative Study of Three Asian Populations. <i>Patient</i> , 2021, 14, 283-293.	1.1	11
22	Trends in Corticosteroid Prescriptions for Ulcerative Colitis and Factors Associated with Long-Term Corticosteroid Use: Analysis Using Japanese Claims Data from 2006 to 2016. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 358-366.	0.6	32
23	Medical costs of Japanese lung cancer patients during end-of-life care. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 769-777.	0.6	4
24	Medical costs of lung cancer care in Japan during the first one or two years after initial diagnosis. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 778-785.	0.6	4
25	Determinants of market prices for drugs under Japan's national health insurance. <i>Journal of Medical Economics</i> , 2021, 24, 1109-1114.	1.0	1
26	Cost-effectiveness of baloxavir marboxil compared to laninamivir for the treatment of influenza in Japan. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 296-305.	0.8	6
27	Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 241.e1-241.e11.	0.6	13
28	Costs and resource use of community-dwelling patients with Alzheimer's disease in Japan: 18-month results from the GERAS-J study. <i>Current Medical Research and Opinion</i> , 2021, 37, 1331-1339.	0.9	5
29	Impact of the Severity of Alzheimer's Disease on the Quality of Life, Activities of Daily Living, and Caregiving Costs for Institutionalized Patients on Anti-Alzheimer Medications in Japan. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 367-374.	1.2	10
30	Cost-effectiveness of baloxavir marboxil compared with laninamivir for the treatment of influenza in patients at high risk for complications in Japan. <i>Current Medical Research and Opinion</i> , 2021, 37, 1135-1148.	0.9	5
31	Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 506.e1-506.e10.	0.6	11
32	COVID-19 and HTA. <i>Japanese Journal of Pharmacoepidemiology/Yakuzai Ekigaku</i> , 2021, 26, 56-62.	0.0	0
33	Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1383-1390.	0.6	9
34	Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan. <i>Expert Review of Vaccines</i> , 2021, 20, 1153-1165.	2.0	7
35	Cost-Effectiveness Analysis of Percutaneous Patent Foramen Ovale Closure Preventing Secondary Ischemic Stroke in Japan. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 105884.	0.7	3
36	Real-World Cost-Effectiveness of Palliative Care for Terminal Cancer Patients in a Japanese General Hospital. <i>Journal of Palliative Medicine</i> , 2021, 24, 1284-1290.	0.6	4

#	ARTICLE	IF	CITATIONS
37	A Systematic Review and Network Meta-Analysis on the Efficacy of Medications in the Treatment of Chronic Idiopathic Constipation in Japan. <i>Gastroenterology Research and Practice</i> , 2021, 2021, 1-13.	0.7	6
38	Epidemiological characteristics of rheumatoid arthritis in Japan: Prevalence estimates using a nationwide population-based questionnaire survey. <i>Modern Rheumatology</i> , 2020, 30, 941-947.	0.9	45
39	Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov Modeling. <i>Crohn's & Colitis</i> 360, 2020, 2, .	0.5	0
40	Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov Modeling. <i>Crohn's & Colitis</i> 360, 2020, 2, .	0.5	0
41	Tu1826 EVALUATION OF EFFECTIVENESS AND COST-EFFECTIVENESS OF COLORECTAL CANCER SCREENING USING COLONOSCOPY, FECAL IMMUNOCHEMICAL TEST, AND A RISK-STRATIFICATION SCORE: A MODELING STUDY. <i>Gastroenterology</i> , 2020, 158, S-1177-S-1178.	0.6	0
42	PMD9 Cost-Minimization Analysis of Robotic-Assisted Surgery for Gastric Cancer Patients in JAPAN. <i>Value in Health Regional Issues</i> , 2020, 22, S60.	0.5	0
43	PMD10 Cost-Utility Analysis of Robotic-Assisted Surgery for Prostate Cancer Patients in JAPAN. <i>Value in Health Regional Issues</i> , 2020, 22, S60.	0.5	0
44	Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis. <i>Advances in Therapy</i> , 2020, 37, 4446-4457.	1.3	5
45	Cost-effectiveness analysis of colorectal cancer screening using colonoscopy, fecal immunochemical test, and risk score. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1555-1561.	1.4	21
46	Cost-effectiveness analysis of treatment regimens with obinutuzumab plus chemotherapy in Japan for untreated follicular lymphoma patients. <i>Journal of Medical Economics</i> , 2020, 23, 1130-1141.	1.0	2
47	Costs and Resource Use Associated with Community-Dwelling Patients with Alzheimer's Disease in Japan: Baseline Results from the Prospective Observational GERAS-J Study. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 127-138.	1.2	14
48	Family caregiving in dementia and its impact on quality of life and economic burden in Japan-web based survey. <i>Journal of Market Access & Health Policy</i> , 2020, 8, 1720068.	0.8	21
49	Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology. <i>International Journal of Clinical Oncology</i> , 2020, 25, 403-417.	1.0	19
50	Cost-effectiveness analysis of postpolypectomy colonoscopy surveillance using Japanese data. <i>Digestive Endoscopy</i> , 2019, 31, 40-50.	1.3	10
51	Cost-utility analysis of a vonoprazan-first strategy versus esomeprazole- or rabeprazole-first strategy in GERD. <i>Journal of Gastroenterology</i> , 2019, 54, 1083-1095.	2.3	15
52	Cost-minimisation model of magnetic resonance-guided focussed ultrasound therapy compared to unilateral deep brain stimulation for essential tremor treatment in Japan. <i>PLoS ONE</i> , 2019, 14, e0219929.	1.1	4
53	Willingness to pay for QALY: perspectives and contexts in Japan. <i>Journal of Medical Economics</i> , 2019, 22, 1041-1046.	1.0	18
54	<p>A Cost-Effectiveness Analysis Of Pregabalin For The Treatment Of Patients With Chronic Cervical Pain With A Neuropathic Component In Japan</p>. <i>Journal of Pain Research</i> , 2019, Volume 12, 2785-2797.	0.8	6

#	ARTICLE	IF	CITATIONS
55	Malnutrition-Related Health Care Cost in Japan: An Analysis of Health Insurance Claims Data. <i>Asia-Pacific Journal of Public Health</i> , 2019, 31, 594-602.	0.4	3
56	Effectiveness of pregabalin for treatment of chronic cervical radiculopathy with upper limb radiating pain: an 8-week, multicenter prospective observational study in Japanese primary care settings. <i>Journal of Pain Research</i> , 2019, Volume 12, 1411-1424.	0.8	6
57	Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: an analysis with real world outcomes from a multicentre cohort in Japan. <i>BMJ Open</i> , 2019, 9, e023405.	0.8	0
58	A retrospective cohort study evaluating healthcare resource utilization in patients with asthma in Japan. <i>Npj Primary Care Respiratory Medicine</i> , 2019, 29, 13.	1.1	25
59	Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1316-1328.	1.4	40
60	Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease. <i>Journal of Gastroenterology</i> , 2019, 54, 718-729.	2.3	36
61	PCN159 COST-UTILITY ANALYSIS OF TRIFLURIDINE/TIPIRACIL FOR HEAVILY PRETREATED METASTATIC GASTRIC CANCER IN JAPAN. <i>Value in Health</i> , 2019, 22, S466.	0.1	0
62	PMH56 THE IMPACT OF PHYSICAL AND MENTAL STRESS ON THE PRODUCTIVITY LOSS IN JAPANESE WORKPLACE. <i>Value in Health</i> , 2019, 22, S690-S691.	0.1	0
63	Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective. <i>Journal of Medical Economics</i> , 2019, 22, 7-15.	1.0	5
64	The association between smoking cessation outpatient visits and total medical costs: a retrospective, observational analysis of Japanese employee-based public health insurance data. <i>Journal of Medical Economics</i> , 2018, 21, 443-449.	1.0	3
65	Economic impact of adalimumab treatment in Japanese patients with rheumatoid arthritis from the adalimumab non-interventional trial for up-verified effects and utility (ANOUVEAU) study. <i>Modern Rheumatology</i> , 2018, 28, 39-47.	0.9	5
66	Preference-Based Health-Related Quality Of Life For Heart Disease Patients In Japan. <i>Value in Health</i> , 2018, 21, S31.	0.1	0
67	Harm of an Electronic Medicine Diary Designed to Manage Data on Prescription at Pharmacies on the Cloud Server and Even More. <i>Value in Health</i> , 2018, 21, S97.	0.1	0
68	Cost-Effectiveness Analysis of Omalizumab Compared With Standard of Care For Severe Allergic Asthma Based On Real World Evidence in Japan. <i>Value in Health</i> , 2018, 21, S104-S105.	0.1	0
69	PIN46 - COST-EFFECTIVENESS COMPARISON OF BALOXAVIR MARBOXIL AND LANINAMIVIR FOR THE TREATMENT OF INFLUENZA IN JAPAN. <i>Value in Health</i> , 2018, 21, S228.	0.1	0
70	COPD uncovered: a cross-sectional study to assess the socioeconomic burden of COPD in Japan. <i>International Journal of COPD</i> , 2018, Volume 13, 2629-2641.	0.9	14
71	Su1016 - Cost-Utility Analysis of Potassium-Competitive Acid Blocker-based Therapeutic Strategy for Gastroesophageal Reflux Disease Compared with Proton-Pump Inhibitor-Based Strategy. <i>Gastroenterology</i> , 2018, 154, S-455-S-456.	0.6	1
72	Preface. <i>Japanese Journal of Pharmacoepidemiology/Yakuzai Ekigaku</i> , 2018, 23, 1-1.	0.0	0

#	ARTICLE	IF	CITATIONS
73	A cost-utility analysis for catheter ablation of atrial fibrillation in combination with warfarin and dabigatran based on the CHADS 2 score in Japan. <i>Journal of Cardiology</i> , 2017, 69, 89-97.	0.8	8
74	Integrating patients'™ perceptions into clinical practice guidelines for the management of rheumatoid arthritis in Japan. <i>Modern Rheumatology</i> , 2017, 27, 924-929.	0.9	6
75	Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUVEAU Study. <i>Advances in Therapy</i> , 2017, 34, 686-702.	1.3	21
76	An exploration of differences between Japan and two European countries in the self-reporting and valuation of pain and discomfort on the EQ-5D. <i>Quality of Life Research</i> , 2017, 26, 2067-2078.	1.5	27
77	Examining the association of smoking with work productivity and associated costs in Japan. <i>Journal of Medical Economics</i> , 2017, 20, 938-944.	1.0	22
78	Transforming Latent Utilities to Health Utilities: East Does Not Meet West. <i>Health Economics (United Tj ETQq0 0 QrgBT /Overlock 10 T</i>	0.8	13
79	Cost-utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan. <i>Current Medical Research and Opinion</i> , 2017, 33, 1-10.	0.9	40
80	Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan. <i>Current Medical Research and Opinion</i> , 2017, 33, 11-21.	0.9	15
81	CHANGES IN SUBJECTIVE BODY PAIN OF FAMILY CAREGIVERS: A COMPARATIVE LONGITUDINAL STUDY. <i>Innovation in Aging</i> , 2017, 1, 809-809.	0.0	1
82	Cancer screening for older people: to screen or not to screen. <i>Hong Kong Medical Journal</i> , 2017, 23, 503-16.	0.1	1
83	Optimal use of colonoscopy and fecal immunochemical test for population-based colorectal cancer screening: a cost-effectiveness analysis using Japanese data. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 186.	0.6	22
84	Simplified Questionnaire for Early Detection of Dementia. <i>Journal of General and Family Medicine</i> , 2016, 17, 83-89.	0.3	2
85	Comparative Effectiveness of Oral Medications for Pulmonary Arterial Hypertension. <i>International Heart Journal</i> , 2016, 57, 466-472.	0.5	17
86	Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan. <i>Journal of Medical Economics</i> , 2016, 19, 1144-1156.	1.0	19
87	Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan. <i>Value in Health</i> , 2016, 19, 648-654.	0.1	180
88	Cost-Effectiveness Analysis of Smoking Cessation Interventions in Japan Using a Discrete-Event Simulation. <i>Applied Health Economics and Health Policy</i> , 2016, 14, 77-87.	1.0	29
89	The process of collecting and evaluating evidences for the development of Guidelines for the management of rheumatoid arthritis. <i>Japan College of Rheumatology 2014: Utilization of GRADE approach. Modern Rheumatology</i> , 2016, 26, 175-179.	0.9	10
90	Profiles of EQ-5D utility scores in the daily practice of Japanese patients with rheumatoid arthritis; Analysis of the IORRA database. <i>Modern Rheumatology</i> , 2016, 26, 40-45.	0.9	19

#	ARTICLE	IF	CITATIONS
91	Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D. <i>Quality of Life Research</i> , 2016, 25, 707-719.	1.5	229
92	Cost-utility analysis of an advanced pressure ulcer management protocol followed by trained wound, ostomy, and continence nurses. <i>Wound Repair and Regeneration</i> , 2015, 23, 915-921.	1.5	9
93	Effects of Prescription Drug Reduction on Quality of Life in Community-Dwelling Patients with Dementia. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2015, 18, 705.	0.9	15
94	Effectiveness of pregabalin for the treatment of chronic low back pain with accompanying lower limb pain (neuropathic component): a non-interventional study in Japan. <i>Journal of Pain Research</i> , 2015, 8, 487.	0.8	25
95	Cost-effectiveness analysis of pregabalin for treatment of chronic low back pain in patients with accompanying lower limb pain (neuropathic component) in Japan. <i>ClinicoEconomics and Outcomes Research</i> , 2015, 7, 505.	0.7	16
96	Postoperative complications in patients with rheumatoid arthritis using a biological agent – A systematic review and meta-analysis. <i>Modern Rheumatology</i> , 2015, 25, 672-678.	0.9	33
97	Relationship between health literacy, health information access, health behavior, and health status in Japanese people. <i>Patient Education and Counseling</i> , 2015, 98, 660-668.	1.0	128
98	Comparison of the Effects of a Brand-name Drug and Its Generic Drug on the Quality of Life of Alzheimer’s Disease Patients. <i>Clinical Psychopharmacology and Neuroscience</i> , 2015, 13, 174-179.	0.9	2
99	Validity and Reliability of the Japanese Version of the Newest Vital Sign: A Preliminary Study. <i>PLoS ONE</i> , 2014, 9, e94582.	1.1	32
100	Cost-minimization Analysis of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients With Primary Immunodeficiency. <i>Clinical Therapeutics</i> , 2014, 36, 1616-1624.	1.1	22
101	Web-based survey on smoking cessation behaviors of current and former smokers in Japan. <i>Current Medical Research and Opinion</i> , 2014, 30, 1911-1921.	0.9	9
102	Cost minimization analysis of beta-blocker at the time of CT imaging for suspected of coronary heart disease in Japan. <i>Journal of Medical Economics</i> , 2014, 17, 142-147.	1.0	2
103	The social costs of child abuse in Japan. <i>Children and Youth Services Review</i> , 2014, 46, 72-77.	1.0	19
104	Cost-Effectiveness Analysis of CT Colonography for Colorectal Cancer Screening Program to Working Age in Japan. <i>Value in Health Regional Issues</i> , 2014, 3, 182-189.	0.5	2
105	FRI0280 – Impact of Disease Duration before Starting Adalimumab Treatment on Work Productivity in Japanese Patients with Rheumatoid Arthritis; Analysis of 24-Weeks Data from the Anouveau Study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 485.1-485.	0.5	1
106	The 14-item health literacy scale for Japanese adults (HLS-14). <i>Environmental Health and Preventive Medicine</i> , 2013, 18, 407-415.	1.4	141
107	WTP for a QALY and health states: More money for severer health states?. <i>Cost Effectiveness and Resource Allocation</i> , 2013, 11, 22.	0.6	81
108	Analysis of direct medical and nonmedical costs for care of rheumatoid arthritis patients using the large cohort database, IORRA. <i>Modern Rheumatology</i> , 2013, 23, 742-751.	0.9	28

#	ARTICLE	IF	CITATIONS
109	Cost-effectiveness Analysis of Microdose Clinical Trials in Drug Development. Drug Metabolism and Pharmacokinetics, 2013, 28, 187-195.	1.1	18
110	Analysis of direct medical and nonmedical costs for care of rheumatoid arthritis patients using the large cohort database, IORRA. Modern Rheumatology, 2013, 23, 742-751.	0.9	10
111	Drug Utilization Reviews by Community Pharmacists in Japan: Identification of Potential Safety Concerns through the Brown Bag Program. Value in Health Regional Issues, 2012, 1, 98-104.	0.5	9
112	2. How to Handle with "Unrelated Cost" in Economic Evaluation?. Japanese Journal of Pharmacoepidemiology/Yakuzai Ekigaku, 2012, 17, 21-26.	0.0	1
113	Potentially inappropriate medication use in elderly Japanese patients. American Journal of Geriatric Pharmacotherapy, 2010, 8, 146-160.	3.0	133
114	Cost-Utility Analysis of Varenicline, an Oral Smoking-Cessation Drug, in Japan. Pharmacoeconomics, 2009, 27, 247-261.	1.7	35
115	Decision Analyses in Consideration of Treatment Strategies for Patients with Biochemical Failure After Curative Therapy on Clinically Localized Prostate Cancer in the Prostate-Specific Antigen Era. Japanese Journal of Clinical Oncology, 2007, 37, 763-774.	0.6	0
116	A Health Economic Evaluation of Aspirin in the Primary Prevention of Cardiovascular Disease in Japan. Internal Medicine, 2007, 46, 157-162.	0.3	20
117	What is ATC/DDD ?. Japanese Journal of Pharmacoepidemiology/Yakuzai Ekigaku, 2004, 9, 53-58.	0.0	3
118	Connective Tissue Growth Factor. Journal of Dermatology, 1992, 19, 642-643.	0.6	14
119	Clinical Significance of Antinuclear Antibodies in Japanese Patients with Systemic Sclerosis. Dermatology, 1990, 180, 136-140.	0.9	15
120	Mitogenic activities for skin fibroblasts in the sera from untreated scleroderma patients at the early stage. Archives of Dermatological Research, 1989, 281, 383-386.	1.1	4
121	Excess Death During COVID-19 Pandemic in Japan: A Preliminary Analysis. SSRN Electronic Journal, 0, , .	0.4	0